# Befotertinib Adjuvant Therapy in Stage IA2-IB NSCLC Patients

> **NCT06561620** · PHASE4 · RECRUITING · sponsor: **Fudan University** · enrollment: 592 (estimated)

## Conditions studied

- 3-year Disease-free Survival

## Interventions

- **DRUG:** Befotertinib

## Key facts

- **NCT ID:** NCT06561620
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-05-01
- **Primary completion:** 2027-05-01
- **Final completion:** 2029-05-01
- **Target enrollment:** 592 (ESTIMATED)
- **Last updated:** 2024-08-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06561620

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06561620, "Befotertinib Adjuvant Therapy in Stage IA2-IB NSCLC Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06561620. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*